Press Centre

September 1, 2017


March 31, 2016

Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada.

March 24, 2016

Apotex Launches First Generic Version of Merck's Nasonex®

Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.

March 16, 2015

Apotex Announces Realignment And Executive Leadership Team To Better Serve The Healthcare Market in Canada And Globally

Dr. Jeremy B. Desai, President and CEO of Apotex, announced today a significant realignment in its structure and operating model. The objective of the realignment is to better serve customers through the establishment of defined lines of business by aligning internal process streams in support of company strategies. Under the new structure, Apotex will now operate along 3 core Lines of Business.

February 17, 2015

ApoPharma Announces Health Canada Approval of Ferriprox (deferiprone)

ApoPharma Inc., today announced that Health Canada has granted approval of Ferriprox (deferiprone), an oral iron chelator for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

February 17, 2015

Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil™)

Apotex Inc., a rising competitor in the global biosimilars market, announced today that, as of February 13th, 2015, the US Food and Drug Administration has accepted for filing the company's application for Filgrastim [Grastofil™], a biosimilar version of Amgen's Neupogen®.

December 17, 2014

Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim

Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that the US Food and Drug Administration has accepted for filing the company's application for pegfilgrastim, a biosimilar version of Amgen's Neulasta®.

September 26, 2014

Setting The Record Straight: Products Are Safe And Effective

Apotex Statement: There has been a great deal of confusion regarding two of our facilities in Bangalore, India. We need to set the record straight. Apotex has two manufacturing facilities located in Bangalore, India.

September 11, 2014

Medicine to Treat 1 in 10 Haitians Arrives in Port-au-Prince

Health officials anticipate that up to 50 percent of the population will be affected by the outbreak. The most recent numbers for Haiti record nearly 65,000 suspected cases. Apotex Inc. donates more than $2.2 M in medical supplies

August 26, 2014

NAFTA Tribunal Decision Supports FDA and Its Actions

Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that an arbitration tribunal rejected Apotex's claims that the FDA violated NAFTA by prohibiting imports of Apotex products from two plants in Ontario, Canada.

October 5, 2012

New Apotex Offices in Saudi Arabia Will Help Expand Trade in Quality, Affordable Pharmaceuticals

Apotex Inc. the largest Canadian owned pharmaceutical company, announced today the opening of new offices in Saudi Arabia to meet the growing demand for affordable quality pharmaceuticals manufactured in Canada.

October 1, 2012

10 Products Divested to AA Pharma

As part of ongoing efforts of reviewing our product portfolio within the evolving generic market landscape, we have made the decision to divest 10 older products within the Canadian market to AA Pharma Inc. Many of these products have been in the market since the 60s and 70s and have been subject to decreasing demand and increasing costs which has placed continued pressure on their commercial viability.

April 2, 2012

Apotex delivers second largest generic blockbuster in Canadian history

Apotex Inc. the largest Canadian owned pharmaceutical company, launched today Apo-Rosuvastatin, a generic version of Crestor® produced by AstraZeneca. The Apotex product is 100% Canadian made by employees and facilities dedicated to ensuring that Canada remains a global strength in generic product introduction. With annual Crestor® brand sales in Canada of over $700 million, generic Rosuvastatin represents the second largest generic product launch in this market to date.

December 8, 2011

$1 billion in savings to Provincial Healthcare budgets and Private Employer Plans with entry of Generic product

Apotex Inc., announced that on December 6, 2011, the Federal Court of Canada ruled in favour of Apotex, clearing the way to deliver their generic version of Plavix®, Apo-Clopidogrel, to the Canadian market. Apotex challenged the Sanofi-aventis Plavix® patents for over 8 years, through two Federal Court systems and multiple levels of judicial review including the Supreme Court of Canada.

November 1, 2011

Launch of the first generic version of Nexium® in Canada, brings billions of dollars of savings to the Canadian Healthcare System

Apotex Inc., the largest Canadian owned pharmaceutical company, launched today Apo-Esomeprazole, a generic version of AstraZeneca's Nexium®, a gastric proton pump inhibitor (PPI). With initial launches to the provinces of Québec, Nova Scotia, New Brunswick, and Ontario, Apotex has now released product to the remainder of the Canadian market. The brand product costs the public and private healthcare budgets close to $300 million per year.

October 11, 2011

Another legal breakthrough - Latanoprost Ophthalmic Solution

Apotex Inc. is pleased to announce its latest successful patent challenge, clearing the way to deliver a generic alternative to Xalatan® to the Canadian market. Following a favorable decision at the Court of Appeal, Apo-Latanoprost was released to the Canadian market on October 3rd 2011, nearly three years prior to patent expiry.

September 14, 2011

ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox® (deferiprone) Approval

On September, 14, 2011, an FDA Advisory Committee voted in favour of approving Ferriprox in the US for patients who have iron overload from blood transfusions, when other chelators are inadequate. This is a major achievement for ApoPharma and the first NDA for the Apotex companies.

July 27, 2011

EU Drug Patent Proposals Would Add $3 Billion Annually To Canada's Prescription Drug Bill

Canada and the European Union (EU) are currently negotiating a comprehensive economic and trade agreement (CETA), which is expected to be concluded by 2012. As part of these negotiations, the EU has tabled proposals that would lengthen the period of market exclusivity for brand-name drugs in Canada by an average of 3.5 years and add nearly $3-billion annually to Canada's prescription drug bill.

May 10, 2011

Apotex Resumes Shipping To The U.S.

Apotex, one of the largest generic pharmaceutical manufacturers in the world, announced it will soon resume shipments of its oral solid dose products to the U.S. market. The announcement comes on the heels of a Food and Drug Administration (FDA) decision to lift its import alert at Apotex's largest solid dose manufacturing facility supplying product to the US.

March 8, 2011

Canada's Access to Medicines Regime Must be Fixed

Toronto, ON - Apotex Inc, Canada's largest pharmaceutical company, today underscored the need for Members of Parliament to fix Canada's Access to Medicines Regime (CAMR) by passing Bill C-393 when it comes up for final vote tomorrow, March 9, 2011. This bill will ensure that CAMR is streamlined and strengthened, and that more affordable life-saving drugs can get to developing countries where thousands of people are dying daily from treatable illnesses.

August 3, 2010

Apotex, Largest Canadian Owned Pharmaceutical Company Sells Group of Products to AA Pharma Inc.

Toronto, ON - Apotex Inc, announced today the sale of more than 40 pharmaceutical products to AA Pharma, a company headquartered in Toronto. Both companies are privately held and no value of the sale was provided. These products represent different therapeutic categories and the sale takes effect as of August 3rd, 2010.

May 19, 2010

Apotex Overcomes Lipitor® Drug Patents Saving Healthcare System Billions of Dollars

Toronto, ON - Apotex Inc, a Canadian owned pharmaceutical company with headquarters in Toronto, launched today Apo-Atorvastatin, a generic version of 'Lipitor®' produced by Pfizer®. This is the largest product to be genericized in Canadian history with approximate yearly sales of $1.2 billion. This last patent on Lipitor® will not expire until 2022. Apotex Inc. invented its own crystal form, thus overcoming the patents, 12 years ahead of time, which will result in close to $7 billion of cost-savings for the Canadian healthcare system.

January 21, 2010

Canadian Company Responds to Haiti Earthquake Relief Efforts with $2 Million of Much Needed Medicines

Toronto, ON - The shipment of medicines included painkillers and antibiotics and is slated to leave this Saturday on an Air Canada flight. An earlier shipment left with a group of 10 doctors working for the relief organization "Feed the Children". The shipment of medicines included painkillers and antibiotics and is slated to leave this Saturday on an Air Canada flight. An earlier shipment left with a group of 10 doctors working for the relief organization "Feed the Children".

October 20, 2009

Apotex to Distribute Important Transdermal System for Management of Chronic Pain in the U.S. Market

Weston, FL - Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain. The Fentanyl Transdermal System, developed by Hisamitsu, is manufactured at the company's state of the art Carlsbad, California facility. The total Fentanyl patch market in the U.S. represents approximately $1.2 billion in sales.

September 18, 2009

Second Shipment Of Life-Saving Aids Drug Leaving For Africa

Toronto, ON - Apotex Inc. today announced that the second shipment of Apo-TriAvir, the generic triple-combination AIDS drug produced to simplify AIDS treatment in developing countries, was leaving for Rwanda, the only country to have benefited from Canada's Access to Medicines Regime (CAMR). CAMR was created by Parliament more than 5 years ago, but because of the costly and complicated process it requires, no other company has come forward to participate in producing more affordable, life-saving generic drugs for export to developing countries.

September 17, 2009

Important Information On Apotex Health Products

Toronto, ON - This communiqué is an update to Health Canada's press release of today's date (7:16 p.m.) relating to three of Apotex's products, Apo-Amilzide (5-50 mg), Apo-Meloxicam (7.5 & 15 mg) and Apo- Ranitidine (75 & 150 mg).

September 8, 2009

FDA Pharmaceutical Import Alert

Toronto, ON - Apotex today issued the following statement concerning an Import Alert issued by the US Food and Drug Administration: The Import Alert recently posted by FDA applies to products manufactured at 2 of Apotex's many facilities. This alert relates to observations made following routine audits for products destined to the US only. We are actively working with the FDA to resolve the identified concerns as quickly as possible, and are optimistic that there will be a prompt resolution.

May 14, 2009

CAMR Federal Law Needs to be Fixed if Life-Saving Drugs for Children are to be Developed

Toronto, ON - Apotex Inc, the largest Canadian-owned pharmaceutical company, reiterated the need to fix the Canada's Access to Medicines Regime (CAMR) if more affordable life-saving drugs are to get to developing countries where thousands of people are dying daily. The regime has not been successful in attaining its original objectives as declared when the law creating it (the Jean Chrétien Pledge to Africa) was passed five years ago this month.

Search by: